Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KWKLFKKIVL
- Development stage
- Preclinical
- Lead developer
- Gerash University of Medical Sciences
- Modality
- Peptides
01
Overview
KWKLFKKIVL is a novel, synthetic ten-amino-acid antimicrobial peptide (AMP) designed through template-based optimization from AMP databases. It exhibits potent broad-spectrum antibacterial activity against Gram-negative pathogens, including carbapenem-resistant Escherichia coli (CRE E. coli), extensively drug-resistant (XDR) Pseudomonas aeruginosa, and Acinetobacter baumannii. The peptide exerts its bactericidal effect primarily through bacterial cell membrane disruption. Preclinical in vitro studies demonstrate high efficacy with low cytotoxicity and hemolytic activity, suggesting a favorable safety profile for potential therapeutic applications.
- Other names
- KWKLFKKIVL peptide
02
Targets
LTA (Lymphotoxin-alpha)
Beyond the preview
Go deeper on KWKLFKKIVL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KWKLFKKIVL.